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ABSTRACT
Motivation: Combination therapies have been widely used to treat cancers. However, it is cost-
and time-consuming to experimentally screen synergistic drug pairs due to the enormous number of
possible drug combinations. Thus, computational methods have become an important way to predict
and prioritize synergistic drug pairs.
Results: We proposed a Deep Tensor Factorization (DTF) model, which integrated a tensor fac-
torization method and a deep neural network (DNN), to predict drug synergy. The former extracts
latent features from drug synergy information while the latter constructs a binary classifier to predict
the drug synergy status. Compared to the tensor-based method, the DTF model performed better in
predicting drug synergy. The area under precision-recall curve (PR AUC) was 0.57 for DTF and 0.24
for the tensor method. We also compared the DTF model with DeepSynergy and logistic regression
models, and found that the DTF outperformed the logistic regression model and achieved almost the
same performance as DeepSynergy using several typical metrics for classification task. Applying the
DTF model to predict missing entries in our drug-cell line tensor, we identified novel synergistic drug
combinations for 10 cell lines from the 5 cancer types. A literature survey showed that some of these
predicted drug synergies have been identified in vivo or in vitro. Thus, the DTF model could be a
valuable in silico tool for prioritizing novel synergistic drug combinations.
Availability: Source code and data is available at https://github.com/ZexuanSun/DTF-Drug-Synergy
∗Corresponding Author
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1 Introduction
Though monotherapy has contributed a lot to helping cure many human diseases, it has several evident drawbacks,
such as acquired resistance or low efficiency [1, 2]. The complexness of human diseases is usually resulting from
the complex interactions of different phenomic and genomic factors. Thus, single drug, which typically targets on
a single protein or pathway, is usually hard to treat the complex diseases well. To solve this dilemma, there comes
combinatorial drug therapy, which uses a pair of or more drugs simultaneously to treat a specific disease. The synergistic
effect of certain drug pairs can potentially improve the curative effect significantly. For instance, pentamidine and
chlorpromazine do not exhibit any traces of inhibiting tumor activities while being used individually, however, the
combination of these two drugs is able to inhibit the growth of tumor efficiently. What’s more, the drugs used for
evaluating drug synergetic effect usually employ existing drugs, which have been studied thoroughly and approved by
Food and Drug Administration (FDA) for treating specific diseases. This will save lots of time for clinical trials of
the safety of these drug combinations. As a result, drug combination therapies have become a more and more popular
treatment option for complex diseases. However, how to identify the drug pairs with drug synergistic effect is still
challenging since the search space of the drug pairs from the drugs approved by FDA is huge. It is too time-consuming
and unrealistic to implement clinical assays on all drug pairs. Therefore, computational methods for predicting drug
pairs with strong synergistic effect are in great demand.
Currently, there are many computational methods for predicting relevant drug pairs. These include both traditional
machine learning methods and deep learning methods. For example, Sidorov et al. proposed models for drug synergy
prediction based on random forest (RF) and extrEme gradient boosting (XGBoost) [3]. The physicochemical properties
of drugs were used as the input of the models. Zhang et al. developed a model, AuDNNsynergy, based on deep learning
method, which took advantage of the gene expression, copy number and genetic mutation data coming from cancer cell
lines to predict drug pairs with high synergistic effect [4].
However, these methods have not made use of structure of the drug synergy data as a multi-way data (e.g. a data
set can be represented as a multidimensional array). In fact, multi-way data reflects a structure of multi-way relations,
which can be best represented as a multi-way array, that is, so-called tensor [5]. Tensor decomposition methods are
utilized to decompose a given tensor constructed from raw data to capture latent re- lations between variables, which
can be used for discovering hidden pat- terns or performing classifications. However, classic algorithms to decom-
pose tensors cannot handle those tensors with missing values, which is a common issue in predicting drug synergetic
effect. Some studies were conducted to solve the problem based on novel tensor frameworks. For example, Chen and Li
proposed DrugCom, a tensor-based model, which incorporated multiple different existing data sources related to drugs
and diseases. DrugCom decomposed a tensor with missing values by integrating existing knowledge at the same time to
get the latent information of drug synergy, and demonstrated a high prediction performance over other methods [6]. Acr
et al. expanded the most well-known tensor factorization method CANDECOMP/PARAFAC (CP) as a weighted least
squares problem that uses a first-order optimization approach to handle the missing values in a given tensor. The new
approach was called as CP Weighted OPTimization (CP-WOPT) [5]. This approach can capture the latent structure of
the data via a higher-order factorization.
Although tensor-based factorization approach is efficient to represent multi-way data, there is still a much need
to improve its prediction performance. Recently, deep learning methods have been shown to predict drug pairs with
high synergy scores. Our study tried to combine tensor-based framework and deep learning methods together to predict
synergetic effect of drug pairs. We proposed a Deep Tensor Factorization (DTF) model, which is comprised mainly by
a tensor factorization method and a deep neural network (DNN). We first use the algorithm, CP-WOPT, to decompose
tensor with missing entries, then the results of the tensor decomposition are served as features to be used to train the
DNN model, which can predict the synergetic effect of drug pairs. This strategy allows the DTF model to capture
the structure of multi-way data and learn more latent information with the help of deep learning method, therefore to
enhance its overall performance.
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2 Materials and Methods
Our model design is shown in Figure 1. The DTF model for synergistic drug combination prediction is based on
two sub-models: a special tensor decomposition model to decompose the tensor with missing values and a DNN model
to predict the drug synergy status.
Figure 1. The workflow of the proposed DTF model. (A) Data collection and preprocessing. The drug-drug synergy
(DDS) data was collected to construct tensor, which was binarized to create synergy status, serving as labels to train the
deep neural net- work. (B) Construct the tensor with missing values and decompose it using CP- WOPT. The results
of the tensor factorization are used as features to train the deep neural network. (C) Build and train the deep neural
network. Use the labels obtained from Step A and the features generated from Step B to train the deep neural network
for predicting the synergy status of a given drug pair.
2.1 Data Collection and Preprocessing
The data we mainly used is the drug-drug synergy (DDS) data derived from ONeil et al.’s study [7]. We got 23,062
drug combinations with the corresponding Loewe synergy scores measured among 38 drugs in 39 cell lines, which
come from 6 human cancer types (Fig. 1. A). We also refer the Loewe synergy score as Loewe additivity.
We used the DDS data to construct the tensor. Since we have three variables, i.e., drug A, drug B and cell line, we
built a 3-order tensor with three axes representing the three variables, respectively. The value of each entity of the tensor
is the synergy score corresponding to a specific drug pair and cell line. We also recorded the positions of the missing
values in the tensor for the convenient of tensor decomposition. For some specific cell lines, there were experiments
carried out multiple times for the same drug pairs. In order to construct the three-dimensional (3D) drug-drug-cell-line
tensor, we averaged these scores for the same drug-drug pairs. It should be also noted that the synergy score of drug A
and drug B is the same as that of drug B and drug A. Therefore, for each cell line the matrix formed by the synergy of
drug pairs is symmetrical. We set the diagonal of each matrix to zero since there is of course no synergistic effect for
the pair of the same drugs.
We also used the DDS data to generate classification labels or synergy status for training the DNN. We select the
threshold as 30, which was used in [8]. That is to say, if the synergy score of a given drug pair is greater than 30, the
synergy status is 1, otherwise, it is 0. We treated the entities with synergy status 1 as positive samples, and those with
synergy status 0 as negative samples. The numbers of positive and negative samples for each cell line are shown in
Figure 2.
2.2 DTF: Deep Tensor Factorization
2.2.1 Notations
We define the dimension of a tensor and multi-way data as order, and refer each dimension as a mode. We use a
lowercase letter (a) to denote a scalar, a boldface lowercase letter (a ) to denote a vector, a boldface capital letter (A) to
3
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Figure 2. Sample size for all cancer cell lines
denote a matrix and a boldface Euler script letter (A) to denote a tensor. Every element of a tensor is denoted by a
lowercase letter with a subscript. For a three order tensor X , its entries can be represented as xijk.
Subarrays (or subfields) can be created by fixing some of the given tensor’s indices. If we fix all but one index,
slices (or slabs) are created. If we fix all but two indices, there come fibers. It is easy to find out that for a third order
tensor each slice is actually a matrix.
We use⊗ to represent a multi-way vector outer product, which is a tensor and each entry of the tensor is the product
of corresponding elements in vectors. For example, the vector outer product of 3 vectors, a, b, c is a three-dimensional
tensor X , where (X )ijk = aibjck.
Say we have two same-sized tensors X and Y , which are of size I1 × I2 × · · · × IN . We define their Hadamard
(elementwise) product asX ∗Y where (X ∗Y)i1i2···iN = xi1i2···iN yi1i2···iN .
For a I1 × I2 × · · · × IN sized tensor X , we define its norm as ‖X‖ =
√〈X ,X 〉. Recall that for matrices and
vectors, ‖ · ‖ can be referred as Frobenius-norm and two-norm, respectively. We are also able to give the definition
of a weighted norm. Say X andW are two same-sized tensors, then we can define theW weighted norm of X as
‖X‖W = ‖W ∗X‖.
If there are a list of matricesA(n) of sizeIn×R for n = 1, · · · , N , the notation
[[
A(1),A(2), · · · ,A(N)]] gives an
I1× I2× · · ·× IN tensor, where (
[[
A(1),A(2), · · · ,A(N)]])i1i2···iN =∑Rr=1∏Nn=1 a(n)inrr , for in ∈ {1, . . . , In} , n ∈
{1, . . . , N}.
The rank of a N-way tensor is 1 if an outer product of N vectors equals to this tensor. A N-way tensor is of rank-1
if it can be strictly decomposed into the outer product of N vectors. We define the rank of a tensor R as the mini- mum
number of rank-one tensors which are required to get X as their sum. For instance, a rank-R 3D tensor can, therefore,
be written as X = ∑Rr=1 ar ⊗ br ⊗ cr = [[A,B,C]]. We refer the matrices A,B,C as factor matrices since they
collect vectors from the rank-one components and hold them as columns. It is known that the problem of computing the
rank of a tensor is NP-hard. Thus, in practice, we cannot know the exact rank of the tensor we investigate.
2.2.2 Tensor Decomposition Algorithms
Rank decomposition is one of the most popular tensor decomposition methods, which stems from the definition
of tensor rank. The key idea underlying rank decomposition is to use the sum of a sequence of rank- one tensors
to approximate the original tensor. CANonical DECOM- Position (CANDECOMP) and the PARAllel FACtors
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(PARAFAC) de- compositions are the most popular rank decomposition approaches, which were proposed in different
knowledge domains independently. Interestingly, both of them follow similar rules, so we usually name the methods as
the CANDE- COMP/PARAFAC or canonical polyadic decomposition (CPD) [9]. For a particular 3D tensor ‖X − X̂‖,
where X̂ =
∑R
r=1 ar ⊗ br ⊗ cr = [[A,B,C]]. Equivalently, for third-order tensors, the CP decomposition can be
treating as optimizing the objective error function as below:
f(A,B,C) =
1
2
I∑
i=1
J∑
j=1
K∑
k=1
(
xijk −
R∑
i=1
airbjrckr
)2
(1)
More details of the algorithm can be found in [9].
a1
1
1
X b
c
+ …~~ +
aR
R
R
b
c
Figure 3. Illustration of CP decomposition.
2.2.3 CP Weighted OPTimization
The CP decomposition method cannot work When a tensor has missing values. Evrim Acar et al. proposed a new
mehtod called CP Weighted OPTimization (CP-WOPT) to solve this problem. The key of CP-WOPT is to introduce
a nonnegtive tensorW . For a three-dimensional tensor with missing values X , we define theW , which is of the
same size as X . For each element ofW , namely, wijk is 1, if if the corresponding element of X , i.e. xijk is known,
otherwise, it is 0. Then we are able to get the weighted version of (1) as follow:
fW(A,B,C) =
1
2
I∑
i=1
J∑
j=1
K∑
k=1
wijk
(
xijk −
R∑
i=1
airbjrckr
)2
(2)
We can easily generalize this to N-way tensor, and get the N-way weighted objective function. LetX be a tensor of size
I1 × I2 × · · · × IN and assume the rank ofX is R. Then we Then we can rewrite the objective function using matrices
as follow:
fW(A(1),A(2), · · · ,A(N)) = 1
2
‖(X −
[[
A(1), A(2), · · · , A(N)
]]
)‖2W . (3)
Our goal is to find matrices A(n) for n = 1, · · · , N that minimize the equation (3). The computation of the
gradient of the fuction can be found in [10]. After having the function and gradient, we can use any gradient-based
optimization method [11] to handle this optimization problem.
We employed a first-order optimization approach, to be specific, the L-BFGS-B algorithm proposed by Richard H
et al., to solve the weighted least squares problem. This algorithm functions as a gold stand- ard tool to solve large
nonlinear optimization problems with simple bounds described. It develops a limited memory BFGS matrix to approach
the Hessian of the objective function. The algorithm was devised to make good use of the form of the limited memory
approximation to carry out the algorithm efficiently [12].
As mentioned previously, the rank of a tensor is often unknown, but results in [13] showed that direct optimization
methods have a better performance than alternating least square approaches when the rank is over- estimated. So
bearing this fact in mind, we can set the number of compo nents R relatively large in the beginning and check the
results of this de composition. If the results are within our tolerance, we decrease R and check the results again. If they
are still good enough, we tend to choose a relatively larger R.
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Similar to CP decomposition, the results of CP-WOPT are a sequence of rank-one tensors. Actually we can collect
the vectors for each dimension and write the results in the form of factor matrices. If the tensor X to be decomposed is
of order 3, the results of CP-WOPT can be represented as [[A,B,C]]. If we pick up the r-th column vectors of these
three matrices, the vector outer product of these three vectors is the r-th rank-one tensor of the results of the CP-WOPT
decomposition. With these rank-one tensors, we are capable of reconstructing the original tensor. Let the sum of these
rank-one tensors be X ′. For each entry of X ′, i.e. x′ijk can written as the sum:
R∑
r=1
airbkrcjr,
where air is the i-th element of the r-th column vector of A, bkr is the k-th element of the r-th column vector of B and
cjr is the j-th element of the r-th column vector of C. For each element of X , xijk, no matter it is known or unknown,
there is en element of X ′, x′ijk, corresponds to it. For the known entries, x′ijk and xijk should be pretty close to each
other, since it is the goal of our optimization. As a result, we can say that each xijk corresponds to a sum of elements
coming from the factor matrices, A, B and C.
2.2.4 Deep Neural Network
The structure of the deep neural network (DNN) we employed in our DTF model is a fully connected neural
network with D layers, where the d-th layer contains Ud neurons. We used rnd to denote the input of the n-th sample
into the d-th layer. Let h(·) be activation function, then the result of activation is and = h(rnd ). Particularly, for the input
layer, an0 = r
n
0 .
Typically, we used forward propagation to calculate the input of next layer. For instance, for the input of (d+ 1)-th
layer (0 ≤ d ≤ D), and+1 can be given by Wda(n)d + bd, where Wd is a Ud+1 × Ud matrix and bd is a bias. We
optimized the parameters of the DNN’s Wd and bd in order to minimize the loss function F =
∑
n loss
(
y′(n), y(n)
)
,
where y′(n) is the predicted probability of the synergistic drug pairs and y(n) is the true synergy status.
We considered different hyperparameter settings for the DNN of DTF. Besides different data normalization
measures, different numbers of the layers and different hidden units inside a layer were studies. Further, we tried
different learning rates and regularization techniques. The considered hyperparameter grid is showed in Table and more
details will be given next.
We tested three different data normalization measures: (i) standardizing all features to zero mean and unit variance,
(ii)standardization and applied hyperbolic tangent and (iii) standardization, hyperbolic tangent and standardization
again. The situation of no data normalization was also considered. The hidden layer utilized relu activations, and the
output layer used sigmoid activation. The binary cross entropy was the loss function to be minimized. We tested two
or three hidden layers, which are summarized in Table 1. We used Adam with learning rate 10−3, 10−4, 10−5, 5 ×
10−3, 5× 10−4, 5× 10−6 as optimizer. Early-stopping and dropout are considered as regularization techniques. For
dropout, we considered dropout rate 0.1,0.2 or no drop out for input layer, and dropout rate 0.1, 0.2, 0.3, 0.4, 0.5 or no
drop out for all hidden layers. We employed grid search to determine the best hyperparameters.
2.2.5 Feature Engineering
The key part of the DTF model is to generate features using the output of CP-WOPT, which is typically known as
feature engineering.
As aforementioned, in the situation of three-dimensional tensor, the decomposition results of CP-WOPT can
be represented using factor matrices [[A,B,C]]. Each matrix collects the latent information of a specific dimension.
In particular, we can say that A collects all the vectors corresponding to the latent information of the first axis, B
corresponding to the second axis, and C corresponding to the third axis. For each known xijk, there is a sum, i.e.,∑R
r=1 airbkrcjr, corresponding to it (Figure 1. B) as we have discussed in last subsection. Obviously, (ai1, · · · , aiR)
is the i-th row vector of A, which can be which can be regarded as features from the latent information of drug A. We
6
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Table 1. Hyperparameter settings considered for DNN of DTF
Hyperparameter Values Considered
Preprocessing no preprocessing; norm; norm + tanh; norm + tanh + norm
Hidden units [1024, 1024, 512], [2048, 2048, 1024], [2048, 1024, 512]
[512, 512, 512], [2048, 2048, 2048], [1024, 1024, 1024]
[2048, 2048], [1024,1024], [512, 512],
[2048, 1024], [1024, 512]
Learning rates 10−3; 10−4; 10−5; 5× 10−3; 5× 10−4; 5× 10−6
Dropout no dropout; input: 0.1, 0.2, hidden: 0.1, 0.2, 0.3, 0.4, 0.5
Note: All possible combinations of the hyperparameters in the table were optimized via grid-search.
applied the same principle to drug B and cell line. Finally, we got three feature vectors (ai1, · · · , aiR), (bk1, · · · , bkR)
and (cj1, · · · , ajR) for a specific xijk. We collected them all together as the features of xijk.
2.2.6 Model Construction
To build the DTF model to predict synergistic drug pairs, we need to link the CP-WOPT and DNN models together.
And the bridge that connects CP-WOPT and DNN models is the feature enngineering described in last subsection. The
overall construction of the DTF model and more details will be given below.
After After data collection and preprocessing, we built the three-order tensor with missing values X derived from
original DDS data. And the three dimensions of the tensor represent drug A, drug B and cell line, respectively. Note
that the value for each element of X is the original drug synergy score rather than the 0/1 labels which were generated
by binarization. The values of the unknown entries of X o not matter, since they were ignored during the computation
process of CP-WOPT. In our model, we simply set them as 0, and we recorded the positions of the missing values in a
position tensor P , which is of the same size as X . A particular entry of P is 1, if the corresponding element of X is
known, otherwise is 0.
Let R be the number of components, then we implemented CP-WOPT on X (Figure 1. B), which required three
parameters: the tensor X to be decomposed, the position tensor P and the number of components R we wish to
decompose the tensor into. As aforementioned, the decomposition results of CP-WOPT can be represented using factor
matrices [[A,B,C]]. Each matrix collects the latent information of a specific dimension. Here, it is resonable for us to
assume that A collects all the vectors corresponding to the latent information of drug A, B corresponding to drug B,
and C corresponding to cell line. Based on the feature engineering mentioned above, we are able to get features for
each synergy score xijk, which can be used to train the DNN.
If we set the number of components of CPWOPT as R, then for drug A, drug B and cell line, the number of
dimension of each of them will be R, which suggests the parameters between the input layer of the DNN and the first
layer is a matrix of size U1 × 3R. The function TRAIN implemented the process of training the DNN, which used
the features generated by the CP-WOPT and the labels from the binarization of synergy scores, namely, the synergy
status. Wd and bd are the parameters of the DNN, which defined the prediction process of the whole model. During the
training process, we employed the classic forward propagation algorithm to calculate the results of the model being
trained and the backward propagation algorithm to derive the gradient of the parameters of the DNN.
After training the DNN model, we used the trained model to predict the synergy status of drug pairs. For each
unknown entry in the original tensor X , it is evident that there are also three feature vectors corresponding to it. These
features are denoted as af , bf , cf , which represent drug A, drug B and cell line features, respectively. And they can be
input into the trained DNN model to predict the synergy status of any given drug pairs. This prediction process was
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implemented in the function PREDICT as shown in Algorithm 1. We used forward propagation algorithm to calculate
the prediction results.
The whole algorithm of our model is shown in the pseudocode of DTF (Algorithm 1). The procedure MODEL
incorporates all the functions to im- plement the prediction of synergy status of drug pairs, where y′ is a vector, which
is used to collect all the predicted probability of the unknown entries.
Algorithm 1 DTF
1: Input: tensor with missing values X , positions of missing values P ,
2: number of component R, synergy labels of drug pairs l;
3: Output: predicted probability of missing pairs y′ ;
4: function PREDICT(af ,bf ,cf ,{Wd}, {bd}):
5: y′ ← forwardprop(af ,bf ,af ,{Wd}, {bd});
6: return y′ . Feature vectors af , bf , cf
7: end
8: function TRAIN([[A,B,C]], l):
9: {Wd} ← init({Wd});
10: {bd} ← {0} ;
11: for epoch← 1 to maxepoch do
12:
{
∂F
∂Wd
}
← 0,
{
∂F
∂bd
}
← 0;
13: for i←mini_batch_indices do
14: y′(i) ← forwardprop(a(i), b(i),c(i),{Wd}, {bd})
15:
{
∂F
∂Wd
}
,
{
∂F
∂bd
}
←
{
∂F
∂Wd
}
,
{
∂F
∂bd
}
+ backprop(a(i),
16: b(i), c(i),y(i),
{
∂F
∂Wd
}
,
{
∂F
∂bd
}
);
17: end
18: {Wd},{bd} ← Adam({Wd},{bd},
{
∂F
∂Wd
}
,
{
∂F
∂bd
}
);
19: end
20: return {Wd},{bd}; . The parameters of deep neural network
21: end
22: procedure MODEL:
23: [[A,B,C]]← CP-WOPT(X ,P ,R); . Tensor factorization
24: {Wd},{bd} ← TRAIN([[A,B,C]],{Wd},{bd});
25: y′ ← [ ]; . Vector to collect the predicting result
26: for i←miss_set_indices do
27: y′(i) ← PREDICT(a(i), b(i), c(i), {Wd} , {bd});
28: y′ ← y′.append(y′(i));
29: end
30: return y′
31: end
2.3 Model and Comparison Evaluation
To evaluate whether the deep learning method, i.e., the DNN is able to do a better job at extracting the latent
information from the DDS data, we compare it with the CP-WOPT baseline model, a classical statistical models for
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for predicting synergy status of drug pairs based on the features generated by CP-WOPT and a state-of-the-art model
proposed to do the the same task as DTF.
• CP-WOPT Baseline Classifier. Generally speaking, CP- WOPT can be treated as a binary classifier alone. Recall
that we can make use of the results to reconstruct the original tensor, and for each unknown synergy status, the sum
corresponding to it can be regarded as a tensor score. Since a higher synergy score means a better synergistic effect
of a given drug pair, we can treat a higher tensor score measured from the re- constructed tensor as stronger synergic
effect of a given drug pair. Hence, for a given threshold of the tensor score, the CP-WOPT can be a binary classifier,
which can served as the baseline model.
• Logistic Regression (LR). Logistic regression model was used to compare DTF with a classical non-linear method.
The features input into the logistic regression model are the same as DNN, which were generated and extracted from
the output of CP-WOPT.
• DeepSynergy. Proposed by Kristina Preuer et al. in 2017, DeepSynergy was definitely a state-of-the art model
to help identify novel synergistical drug pairs. DeepSynergy uses chemical and genomic information as input
information, a normalization strategy to account for input data heterogeneity, and conical layers to model drug
synergies [8]. We used the same input data as DeepSynergy. Note that the DeepSynergy utilized more datasets than
the DTF. And the DeepSnergy is originally intended to solve the regression problem, to revise it into a classifier, we
chose 30 as the threshold to binarise the predicted synergy scores for consistency. And we used the DNN with the
best architecture propsed by Kristina Preuer et al. in this comparison.
Due to the fact that all the models to be compared cannot discern the drug combinations AB, represented in order A-B
or B-A, we double the sample. To benchmark the performance of DTF with other methods, we employed a particular
stratified cross validation method, where the drug combinations were chosen to leave out in test sets [8]. Under this
circumstance, a given drug pair selected in the test set in a cell line is also included in the training set of all other cell
lines. Note that since the DTF model is integrated, in the crooss validation process, different tensors were composed
and each time the features for a particular drug pair can be different.
2.4 Software and Global Parameters
CP-WOPT was implemented in Matlab tensor_tool box version 3.1 and the Matlab wrapper of L-BFGC-B was
written by Stephen Becker [14]. We employed the Keras version 2.2.4 and scikit-learn version 0.21.3 to implement the
DNN model and other machine learning models.
The tensor we constructed is of order 3, which has 3 axes, representing drug A, drug B and cell line. The dimension
of drug A and drug B is 38, and that of cell line is 39. The number of components to be decomposed R was set to 1000.
Hence, the dimension of the input features the DNN model is 3000. The threshold we choose to binarize drug synergy
score is 30.
The numerical calculations in this paper have been partially done on the supercomputing system in the Supercom-
puting Center of Wuhan University. Thanks Supercomputing Center of Wuhan University for supporting the numerical
calculations of this paper.
3 Result
3.1 DNN Architecture
The architecture of the DNN of DTF was determined via grid-search. This process showed that the second
normalization strategy, standardization and applied hyperbolic tangent, performed best. Furthermore, the coinc layers,
where the number of hidden units decreases half in each hidden layer, have a better performance. A possible explanation
for the fact that coinc layers are better, is their effect in regularizing. The smaller number of parameters in the higher
layers pushes the model to be more general by extracting the most important latent information of the input features,
generated by CP-WOPT. What’s more, a coinc layers with more layers work well, namely, the one has three hiddern
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layers. A relateive small learning rate (10−5) and dropout techonique were also critical for the DNN of the DTF to do a
good job. In general, the DNN of DTF has a conic architecture with three hidden layers, having 2048 units in the first,
1024 in the second and 512 in the third layer. It employs standardization and applied hyperbolic tangent normalization
method, has a learning rate of 10−5, and has dropout rates, 0.2, 0.5 for input and hidden layer, respectively.
3.2 Method Comparison
We used CP-WOPT algorithm to decompose the tensors generated from the stratified cross validation method
mentioned above. After the tensor factorization, we got features of drug A, drug B and cell line and also the tensor
score of each drug pair. The factorized features from the CP-WOPT were used to build the classification models of DTF,
LR and CP-WOPT. For DeepSynergy, we considered the same test sets and used the best architecture propose in [8].
We chose metrics that are typical for classification task: area under the receiver operator characteristics curve
(ROC AUC), area under the precision recall curve (PR AUC), accuracy (ACC), balanced accuracy (BACC), precision
(PREC), sensitivity (TPR), and Cohen’s Kappa. The threshold to binarilize the synergy score is the 90% percentile [8],
we chose in this paper. Therefore, in order to compute some of the metrics the tensor scores were binarilized using
also the 90% percentile of the tensor scores. And we binarilized the predicting probability with threshold 0.5. The
reuslts are summerized in Table 2. Obviously, DeepSynergy had the best overall performance among all methods,
Table 2. Methods comparision results based on performance metrics for the classification task.
Performance Metric ROC AUC PR AUC ACC BACC PREC TPR Kappa
DTF 0.89±0.02 0.57±0.04 0.93±0.01 0.67±0.03 0.73±0.03 0.36±0.07 0.45±0.06
DeepSynergy 0.90±0.02 0.60±0.05 0.93±0.01 0.67±0.03 0.72±0.04 0.36±0.05 0.44±0.05
Logistic Regression 0.83±0.02 0.38±0.05 0.92±0.01 0.57±0.03 0.63±0.06 0.16±0.06 0.22±0.06
CP-WOPT 0.67±0.11 0.24±0.09 0.86±0.03 0.61±0.07 0.26±0.08 0.31±0.13 0.20±0.11
Note: All values are average values±one standard deviation. We used bold font to represent the best and performance
values. And bold with itlatic font was used to represent the sencond best performance values. The performance
metrics provided are area under ROC curve (ROC AUC), area under precision-recall curve (PR AUC), accuracy (ACC),
balanced accuracy (BACC), precision (PREC), sensitivity (TPR) and Kappa.
achieveing a ROC AUC, PR AUC, ACC, BACC, PREC, TPR, and Kappa of 0.90, 0.60, 0.93, 0.67, 0.72, 0.36, and 0.44,
respectively. However, DTF exhibited a slightly inferior performance than DeepSynergy. The percision of DTF even
had a higher performance than DeepSynergy. And DTF achieved the same values as DeepSynergy in ACC and BACC
metrics. Needless to say, CP-WOPT baseline classifier model did the worst job here. And Logistic Regression model
helped to improve the performance of CP-WOPT. But compared to DTF, the improvement was far behind.
To sum up, DNN significantly improved the performance of CP-WOPT. And more importantly, with far less data
sets, namely smaller size of the input data, the DTF model, which combines DNN and CP-WOPT achieved a good
performance almost the same as DeepSynergy in this comparison conditions.
3.3 Order independence
Drug combinations were doubled to DTF. We used both orders (drug A - drug B and drug B - drug A) for training
and predicting. Undoubtedly, each pair was input into the DNN twice. The predicting results for the two different ways
of ordering is shown in Figure 4. Most of the values assemble around the original point, not too many points lied in the
middle of [0,1] and a few gathered around the point (1,1), which is reasonable, since the data set is highly imbalanced
after preprocessing. All points sat approximately two sides around the identity line, even though they are not quite close
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Figure 4. Scatter plot of the predictions derived from the two different orderings of drug pairs. X-axis represents
the ordering drug A - drug B - cell line, and Y-axis represents drug B - drug A - cell line. The Pearson correlation
coefficient between the two predictions is 0.95.
to it. The predicting results of two different ordering achieved a Pearson correlation coefficient 0.95, which exhibits that
the DTF can ignore the order of the drug pair.
3.4 Prediction of the Drug Pairs with Unknown Synergy Status
The results above have shown that the DTF model we built is able to learn the relationship between the constructed
tensor and the known synergy status of the drug pairs and the order of drug combinations can be neglected , which
means that we can reliably apply the model to predict the synergy status of the drug pairs we do not have synergy scores
experimentally measured.To do this, we first constructed the tenor using approximately 90% drug pairs with known
synergy scores and then built the DTF-based prediction model based on the factorized features from the tensor. The
about 10% of the drug pair with known synergy scores were used for final validation.
Using the same cutoff of 0.5 as we used for model evaluation, on validation set, DTF achieved, ROC AUC, PR
AUC, ACC, BACC, PREC, TPR, and Kappa of 0.90, 0.66, 0.93, 0.77, 0.66, 0.58, and 0.57, respectively. This ensured
that our predictions on those drug combinations with synergy scores known were convincing. As a result, there 39 drug
combinations out of 4680 drug combinations with unknown synergy scores are predicted with a probability of highly
synergistic higher than 0.5. The results are exhibited in Table 3. Since here we what we predicted was the probability
of highly synergistic drug pairs, it is reasonable to have relative small results with a probability above 0.5 to be highly
synergistic.
Table 3. Top predicted synergistic drug pairs.
Cell line Cancer Drug A Drug B Probility
CAOV3 Ovarian Dexamethasone Etoposide 0.99950922
CAOV3 Ovarian Cyclophosphamide Etoposide 0.99790645
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CAOV3 Ovarian Etoposide SN-38 0.99739087
CAOV3 Ovarian Carboplatin Etoposide 0.98608768
CAOV3 Ovarian 5-FU Etoposide 0.98177201
CAOV3 Ovarian Etoposide Metformin 0.96313089
CAOV3 Ovarian Etoposide Mitomycine 0.94149995
OV90 Ovarian SN-38 Vinorelbine 0.92593026
CAOV3 Ovarian Etoposide Topotecan 0.90996122
OV90 Ovarian Topotecan Vinorelbine 0.90770292
CAOV3 Ovarian Etoposide Vinblastine 0.9032594
NCIH460 Lung Etoposide Paclitaxel 0.89135432
HT144 Melanoma Etoposide Paclitaxel 0.87608039
A375 Melanoma Etoposide Paclitaxel 0.86257684
CAOV3 Ovarian Cyclophosphamide Dexamethasone 0.82120794
SKMES1 Lung Dexamethasone Paclitaxel 0.80908144
CAOV3 Ovarian Doxorubicin Etoposide 0.79553449
HT144 Melanoma Etoposide Topotecan 0.79118788
CAOV3 Ovarian Etoposide Paclitaxel 0.77346706
CAOV3 Ovarian Etoposide Oxaliplatin 0.74256992
KPL1 Breast Carboplatin Dexamethasone 0.69261187
OV90 Ovarian Paclitaxel Vinorelbine 0.6880514
ES2 Ovarian Paclitaxel Vinblastine 0.6860581
OV90 Ovarian Etoposide Vinorelbine 0.67436397
KPL1 Breast Dexamethasone Vinblastine 0.67418796
VCAP Prostate Etoposide Topotecan 0.66042769
OV90 Ovarian Mitomycine Vinorelbine 0.63128829
OV90 Ovarian Carboplatin Vinorelbine 0.63081199
OV90 Ovarian Vinblastine Vinorelbine 0.60110456
KPL1 Breast Dexamethasone SN-38 0.59713888
CAOV3 Ovarian Etoposide Vinorelbine 0.58822578
SKOV3 Ovarian Dexamethasone Vinblastine 0.57798028
NCIH460 Lung Paclitaxel SN-38 0.55808449
CAOV3 Ovarian Dexamethasone SN-38 0.55116999
VCAP Prostate Etoposide Vinblastine 0.55102927
OV90 Ovarian Cyclophosphamide Vinorelbine 0.5375827
A375 Melanoma Etoposide Vinorelbine 0.53126353
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VCAP Prostate Topotecan Vinblastine 0.50386643
VCAP Prostate SN-38 Vinblastine 0.50151283
4 Discussion
Our predicted high probability of synergistic pairs are consistent with previous studies. Examples of these are
as following. Etoposide and dexamethasone, shows the highest predicted probability of synergy among the 23 pairs
in the ovarian cancer cell line CAOV3. Etoposide is a DNA topoisomerase II inhibitor and has been approved by
FDA for treating testicular and lung cancers [15]. Oral etoposide has demonstrated efficacy as an advanced treatment
option for platinum-resistant ovarian cancer patients [16] and also as a maintenance chemotherapy for advanced ovarian
cancer patients to improve the survival outcomes [17]. Dexamethasone is a steroid used to reduce inflammation.
Dexamethasone is a type of steroid medication that has powerful anti-inflammatory and immunosuppressant and has
been used in cancer treatment [18]. A recent study has confirmed the efficacy of the etoposide and dexamethasone
combination therapy in hemophagocytic lymphohistiocytosi treatment [19]. Therefore, combining dexamethasone and
etoposide may improve the efficacy of etoposide as a single agent for the ovarian cancer treatment.
Since the DTF model employed just a single data set, the conciseness of the model may be enhanced, however, the
interpretability of the model and the results may be reduced. In the future, we are interested in expanding the model to
incorporate more information resources into the DTF model to improve the interpretability of DTF model. More effort
will be put into investigating the other structures of the DNN for the sake of improving the performance of the entire
model.
5 Conclusion
There are two key steps for the proposed DTF model, 1) decomposing the tensor with missing entries constructed
from the original drug synergy data to generate features of drugs and cell lines using the CP-WOPT algorithm; and 2)
training the DNN model using the factorized features together with the observed labels (synergetic status of the drug
pairs) to predict the synergistic effect of the drug pairs with unknown synergetic scores. The DTF method, by linking
the CP-WOPT and the DNN, used only a single data source but significantly improved the performance of CP-WOPT.
In addition, the DTF model achieved almost same prediction performance as the state-of-the-art model, DeepSynergy,
using far fewer data sets, suggesting its potential as a valuable tool for predicting and optimizing synergistic drug pairs
in silico and thus guiding in vitro and in vivo discovery of rational combination therapies.
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